GDF15 and heart failure: Indeed, in a randomized controlled clinical trial of sacubitril/valsartan, which prevents adverse cardiac remodeling, reduces heart failure morbidity and mortality, and reduces indices of cardiac stress, GDF15 was not different in placebo and experimental arms (155).